Generic Name and Formulations:
Anthralin 1.2% (microcrystalline encapsulated); rapid-release cream.
Indications for ZITHRANOL-RR:
Stable plaque psoriasis.
Initially apply once daily (5–15 minutes contact time) for at least one week; may increase contact time to 30 minutes before washing off. Individualize. For skin: use sparingly. For scalp: wash and rinse hair; apply cream while hair is damp; may repeat treatment on alternate days.
Acute or actively inflamed psoriatic eruptions.
Avoid eyes, mucous membranes. Apply cautiously on the face or intertriginous skin areas. Discontinue if sensitization or excessive irritation develops. May stain fabrics; avoid. Pregnancy (Cat.C). Nursing mothers.
Possible contact allergic reactions, discolored hair or fingernails.
Endocrinology Advisor Articles
- Imaging Studies in Hypothyroidism Evaluation Linked to Unnecessary Risks
- Insulin Glargine Associated With Breast Cancer Risk in T2D
- Once-Weekly Omarigliptin Improves Glycemic Control in Type 2 Diabetes
- Transoral Endoscopic Thyroidectomy Vestibular Approach: Safety and Outcomes
- High Grip Strength Associated With Lower Risk for Diabetes-Related AEs
- Update on Vitamin D and Calcium Supplements for Reducing Fracture Risk
- Lower Risk for SGLT2i-Associated Genitourinary Infection With DPP-4i
- Severe Hypoglycemia Associated With Increased Mortality Risk in T2D
- Efficacy of CGM in Preterm Infants of Mothers With Diabetes
- Expert Roundtable: AHA Update on Dietary Fat Intake and CVD Risk
- Increased Risk of Diabetes, Post-Diabetes Pneumonia for Patients With COPD
- Pancreatic Exocrine Dysfunction Occurs After Islet Autoimmunity in T1D
- T2D in African American Women Ups ER-negative Breast Cancer Risk
- High-Sensitivity CRP and LDL-C Predictive of Subsequent MACE in T2D
- Risks Associated With Denosumab Discontinuation